When several weak links become disease

Paper 8B · Compound Race Pathology · Read on Zenodo

We have known for decades that cancer is rarely one button being pressed. It is a series of steps, each a small push toward disease, which is why a combination of drugs usually beats a single one. This paper proposes that this shape, many small steps adding up without any one step holding all the control, is not special to cancer. It may be the shared shape behind a whole group of hard, long-running diseases. It is a hypothesis and an invitation to test it. It is not medical advice, and it does not tell any particular patient what to do.

Disease as many small races, not one

The framework builds on the same picture as the rest of the site, the one I describe through learning. A system is full of small races: several possible outcomes run at the same time, and the one that reaches the finish first wins. Every time an outcome wins, it digs its track a little deeper, so it wins more easily next time. How quickly a race is settled depends on the pressure: the more worked up the system is, the faster the decision falls, and the more the route with the deepest track wins.

Paper 8 used that picture on one person, where the layers sit on top of each other from the biology at the bottom to the thoughts at the top. This paper moves the focus to the body's biological scales: molecules, cells, tissues, organs, and the whole organism. Races run on every scale. A molecular race can tip a cell, a cell race can tip a tissue, and so on upward. Disease, in this reading, is not one race going wrong. It is many races on many scales, each tipping a little, coupled together so that a track on one scale shifts the starting point for the others.

Control is shared

The new piece in the paper is a point borrowed from biochemistry. When you measure how much each step in a metabolic chain governs the total flow, it turns out that control is spread out. The shares add up to a whole, and there is usually no single step that holds it all. The idea of the one all-deciding bottleneck step rarely holds (this is called metabolic control analysis, and the shares sum to one).

The paper carries that structure over to disease. Think of how fast a disease progresses as the thing that corresponds to the flow. Each scale then holds a share of the control over the progression, and the shares add up to a whole. The consequence is concrete: a drug that hits one target on one scale can at best move its own share and no more. If control is genuinely spread out, so that no scale holds almost all of it, then one target is mathematically bound to fall some way short of cure, while a combination that spreads across several scales can reach further than any single target can.

This is the mechanical reason for a pattern clinicians have long known: that combination treatment often beats a single drug. Chemotherapy is given in combination. Modern treatment of heart failure rests on several pillars at once. The framework does not claim it is new to treat with several targets. It gives a reason for why it works.

The same shape across several diseases

The paper works through four groups of disease as versions of the same shape:

• Cancer: the cleanest example, because the steps are already mapped. The classic stepwise progression from benign to malignant (mutations that accumulate, one at a time) and the well-known hallmarks of cancer are read here as races, the cancer cell having to win against the body's control, where each mutation is a track that tips the next race. That is why hitting one single pathway rarely suffices.
• Autoimmune diseases (rheumatoid arthritis as the example): read as compound tipping points, where several scales (heredity, environmental triggers, a break in immune tolerance, inflammation in the tissue) add up, and the disease tips when the combined load crosses the threshold. The fact that patients differ so much is explained as a difference in which scales weigh most in each individual. It is also why one biologic drug helps some and not others.
• ME/CFS and long COVID: read as a multi-scale imbalance after a virus. The infection pushes several coupled scales (the immune system, the autonomic nervous system, metabolism, mitochondria) away from their starting point, and hysteresis holds them there, even after the virus is gone. Worsening after exertion is read as exertion raising the pressure on scales that are already displaced, so they tip further away instead of recovering.
• Treatment-resistant depression: read as an extension of Paper 8. The resistance arises when the condition is carried by several coupled scales at once (for example a biological inflammation scale, an autonomic scale, and a ruminating scale) instead of by one. It explains why a patient may fail to respond to a drug that mostly hits one scale: the scales that go untreated keep the disease running.

The point is not to erase the difference between a cancer and a depression. It is that if the same shape lies underneath, then a way of intervening that works in one corner may be worth trying in another. That is the kind of prediction the framework exists to make testable.

Where the simple picture falls short

The simple version, where the shares just add up, only holds part of the way, and the paper is open about it. Three patterns break with the clean sum:

• Cascade: when the scales are coupled so that a failure on one triggers a failure on the next, the progression can jump rather than rise smoothly. Here one well-placed intervention early in the cascade can have a large effect.
• Saturation: when a scale's contribution is close to bottoming out, it does not help to give more of the same drug, no matter how large that scale's share otherwise is.
• Interaction: when the scales play together, a combination can give more than the sum of its parts, so combination treatment beats even the additive expectation.

Heart failure with reduced pumping function is used as the honest borderline case. Its treatment is already built on several pillars, which the framework reads as the clinic having arrived on its own at treating with several targets. But the disease has both cascade traits and saturation traits, so the clean sum does not capture it. The paper uses it as both support and as a limit on how far the simple picture reaches.

What you can do follows from the mechanics

Because control is shared, an intervention that is to work usually has to hit several scales, not just the one target as hard as possible. The paper sorts interventions by which part of the mechanics they hit:

• Lower the pressure or raise the threshold, so the races are not settled so easily in the diseased direction. The biological base interventions from Paper 8D belong here.
• Build competing routes: add new experience that can in time win instead of the diseased route. This rests on a point that recurs across the whole framework: you cannot subtract a track again, only add a new one beside it.
• Prevent the race from starting: remove the triggering signals, intervene before the pressure crosses the threshold. Prevention is mechanically stronger than cure, because once the race has been settled in the diseased direction and laid its track, it is too late for that particular case.

What it means (and does not mean)

This is a hypothesis and an invitation, not a treatment manual. The paper sets out ten testable predictions, two of which (called R3 and R5) are pivotal for the framework: if they do not hold, the whole idea of compound race pathology falls. Several of the predictions can be examined on already-collected data, without gathering new data. That is how a framework like this is meant to be used: it says what can be tested, not what a particular person should do.

And it should be read as a theoretical framework about the mechanism, not as a diagnostic manual or medical advice. It does not replace a professional assessment of the individual person. If something here rings true about you or someone you care about, then it is a conversation to have with a professional, not a conclusion to draw from a website.

What I don't know

There is no clinical co-author on the paper yet, and that is a real limitation: the framework is built by a theorist, not tested in a clinic. No new data was collected either. It is a gathering of existing findings from separate research fields, set together under one mechanism.

The shares of control the framework talks about have not been measured. The framework predicts that they are spread out, but it does not deliver the numbers, and those have to come from studies built to measure them. The most concrete biological claims (for example about which cofactors and which scales weigh most in which disease) are framed as predictions, not as something that has been proven. And the maths is deliberately simplified. It shows the shape of the mechanism, additive shares in the simple regime, but it is not calibrated to give numbers you can compute further from, and the three more involved patterns are included precisely because the clean sum is known not to be the whole story. The next step is collaboration with people who can test the predictions properly.

Read the paper

The full article is freely available on Zenodo (concept DOI 10.5281/zenodo.20059869):

Read on Zenodo → · Technical version · Dansk version

Related on this site:

• Paper 1 (Friction Theory) — the framework behind races and tracks, which this paper builds on.
• The Learning page — the same mechanics from the opposite end: how tracks get built.
• The Memory page — why a dug track fades, and what keeps it alive.

The family of clinical papers (same framework, different angles):

• Paper 8 (Pressure, Hysteresis, and Experience) — the clinical foundation: races, tracks and pressure in one person, and the principle of treating at the base.
• Paper 8C (Research Program) — concrete study designs that can measure the control shares and test the predictions against reality.
• Paper 8D (Treating the Base) — the preventive side: cofactors and biological base below the diagnostic threshold.